Telomir Pharmaceuticals在侵袭性人类前列腺癌细胞模型中报告了新的临床前癌症数据，表明Telomir-1抑制了CDKN 2A（主要肿瘤抑制基因-8 K文件）的DNA超甲基化

2025-09-09 19:49

CDKN2A plays a central role in controlling uninhibited cell growth and initiating programmed cell death, and its silencing is a well-established hallmark of cancer progression.
Telomir-1 outperformed both Rapamycin and chemotherapy in inhibiting DNA hypermethylation of CDKN2A in the in vivo human prostate cancer model. These findings build upon previously reported data showing that Telomir-1 also resets DNA methylation of STAT1, a master immune regulator silenced in aggressive cancers.
Together, the STAT1 and CDKN2A results demonstrate Telomir-1's ability to reset epigenetic silencing across multiple tumor suppressor pathways. This dual effect addresses two of cancer's most fundamental escape mechanisms: unchecked cell proliferation and immune evasion.
Telomir is actively assessing Telomir-1 across multiple aggressive cancers beyond prostate, with additional studies underway. The company's pre-IND program is running in full gear, with CMC activities scaling up toward GMP production and IND-enabling studies ongoing as Telomir moves toward its first IND submission.